Logo image of ARNA

ARENA PHARMACEUTICALS INC (ARNA) Stock Fundamental Analysis

USA - NASDAQ:ARNA - Common Stock

99.99
+0.06 (+0.06%)
Last: 3/10/2022, 8:10:48 PM
99.99
0 (0%)
After Hours: 3/10/2022, 8:10:48 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to ARNA. ARNA was compared to 534 industry peers in the Biotechnology industry. ARNA has a bad profitability rating. Also its financial health evaluation is rather negative. ARNA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ARNA had negative earnings in the past year.
ARNA Yearly Net Income VS EBIT VS OCF VS FCFARNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M -200M 400M -400M -600M

1.2 Ratios

Industry RankSector Rank
ROA -78.55%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ARNA Yearly ROA, ROE, ROICARNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 -50 -100 -150 -200

1.3 Margins

ARNA does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) -1141511.11%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ARNA Yearly Profit, Operating, Gross MarginsARNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -200K -400K -600K -800K -1M

More info and screens

3

2. Health

2.1 Basic Checks

ARNA has more shares outstanding than it did 1 year ago.
ARNA has a worse debt/assets ratio than last year.
ARNA Yearly Shares OutstandingARNA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M
ARNA Yearly Total Debt VS Total AssetsARNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M 800M 1B

2.2 Solvency

ARNA has an Altman-Z score of 27.53. This indicates that ARNA is financially healthy and has little risk of bankruptcy at the moment.
A Debt/Equity ratio of 0.05 indicates that ARNA is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 27.53
ROIC/WACCN/A
WACCN/A
ARNA Yearly LT Debt VS Equity VS FCFARNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 500M -500M 1B

2.3 Liquidity

ARNA has a Current Ratio of 8.59. This indicates that ARNA is financially healthy and has no problem in meeting its short term obligations.
ARNA has a Quick Ratio of 8.59. This indicates that ARNA is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 8.59
Quick Ratio 8.59
ARNA Yearly Current Assets VS Current LiabilitesARNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for ARNA have decreased strongly by -19.46% in the last year.
Looking at the last year, ARNA shows a very negative growth in Revenue. The Revenue has decreased by -82.00% in the last year.
Measured over the past years, ARNA shows a very negative growth in Revenue. The Revenue has been decreasing by -77.43% on average per year.
EPS 1Y (TTM)-19.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.81%
Revenue 1Y (TTM)-82%
Revenue growth 3Y-85.58%
Revenue growth 5Y-77.43%
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -2.25% on average over the next years.
ARNA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 439.46% yearly.
EPS Next Y2.6%
EPS Next 2Y3.11%
EPS Next 3Y-0.06%
EPS Next 5Y-2.25%
Revenue Next Year4629.54%
Revenue Next 2Y1075.64%
Revenue Next 3Y597.1%
Revenue Next 5Y439.46%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ARNA Yearly Revenue VS EstimatesARNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
ARNA Yearly EPS VS EstimatesARNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ARNA. In the last year negative earnings were reported.
Also next year ARNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ARNA Price Earnings VS Forward Price EarningsARNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -10.44
ARNA Per share dataARNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.11%
EPS Next 3Y-0.06%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ARNA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARENA PHARMACEUTICALS INC

NASDAQ:ARNA (3/10/2022, 8:10:48 PM)

After market: 99.99 0 (0%)

99.99

+0.06 (+0.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)05-03 2022-05-03
Inst Owners0%
Inst Owner Change0%
Ins Owners3.08%
Ins Owner Change0%
Market Cap6.17B
Revenue(TTM)54.00K
Net Income(TTM)-616416000
Analysts69.47
Price Target99.8 (-0.19%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 114173.77
P/FCF N/A
P/OCF N/A
P/B 9.16
P/tB N/A
EV/EBITDA -10.44
EPS(TTM)-8.84
EYN/A
EPS(NY)-8.61
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS10.92
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -78.55%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -1141511.11%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.59
Quick Ratio 8.59
Altman-Z 27.53
F-Score1
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-19.46%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.81%
EPS Next Y2.6%
EPS Next 2Y3.11%
EPS Next 3Y-0.06%
EPS Next 5Y-2.25%
Revenue 1Y (TTM)-82%
Revenue growth 3Y-85.58%
Revenue growth 5Y-77.43%
Sales Q2Q%N/A
Revenue Next Year4629.54%
Revenue Next 2Y1075.64%
Revenue Next 3Y597.1%
Revenue Next 5Y439.46%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

ARENA PHARMACEUTICALS INC / ARNA FAQ

Can you provide the ChartMill fundamental rating for ARENA PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ARNA.


Can you provide the valuation status for ARENA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to ARENA PHARMACEUTICALS INC (ARNA). This can be considered as Overvalued.


How profitable is ARENA PHARMACEUTICALS INC (ARNA) stock?

ARENA PHARMACEUTICALS INC (ARNA) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ARENA PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ARENA PHARMACEUTICALS INC (ARNA) is expected to grow by 2.6% in the next year.